Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Rob Jones

- PMLiVE

How the WHO hepatitis strategy measures up in the field

With hepatitis cases on the rise, Dr Anthony Martinez, member of the International Hepatitis Education Program (IHEP), shares his perspective on the World Health Organization’s new strategy for hepatitis elimination...

Avalere Health

- PMLiVE

Merck and Orna agree on deal worth $3.5bn for RNA technology

The companies will work together to develop proprietary circular RNA technology

- PMLiVE

AstraZeneca and Merck’s Lynparza combination therapy receives FDA priority review in first-line prostate cancer

Prostate cancer is the second most common cancer in male patients in the US, projected to cause around 35,000 deaths in 2022

- PMLiVE

bluebird bio’s beta-thalassaemia gene therapy receives FDA approval

Patients with the most severe form of the blood disorder develop life-threatening anaemia and have to receive regular blood transfusions

- PMLiVE

GSK’s application for momelotinib in myelofibrosis with anaemia accepted by FDA

40% of myelofibrosis patients are already anaemic at the time of diagnosis and nearly all patients are estimated to develop anaemia eventually

- PMLiVE

Bristol Myers Squibb successfully completes acquisition of Turning Point Therapeutics

The deal offers BMS a pipeline of investigational medicines to expand its oncology portfolio, including repotrectinib

- PMLiVE

Hanover Health appoints James Mole as a director

Mole previously served as deputy director of communications at NHS England

- PMLiVE

Are we the masters or servants of omnichannel engagement?

I think very few people will have failed to notice that our industry is currently in somewhat of a turmoil, as each company and team look at how they can...

- PMLiVE

AstraZeneca and Daiichi Sankyo’s Enhertu shows significant improvement for breast cancer patients

The phase 3 trial compared Enhertu against a treatment pre-determined by physicians in people with HER2-positive metastatic breast cancer

- PMLiVE

JCVI publishes advice on COVID-19 vaccines ahead of autumn booster campaign

The programme was expanded in response to the Omicron variant to include everyone aged 50 and over

- PMLiVE

Gilead Sciences announce positive results for Trodelvy in breast cancer patients

HR+/HER2- breast cancer accounts for around 70% of all new cases, or nearly 400,000 diagnoses worldwide each year

- PMLiVE

UK government to launch national mission to tackle dementia

One million people are predicted to be living with dementia by 2025

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links